P. Venner

1.8k total citations · 1 hit paper
12 papers, 1.3k citations indexed

About

P. Venner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, P. Venner has authored 12 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in P. Venner's work include Prostate Cancer Treatment and Research (11 papers), Bone health and treatments (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). P. Venner is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Bone health and treatments (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). P. Venner collaborates with scholars based in Canada, United States and Australia. P. Venner's co-authors include Joseph L. Chin, Robin Murray, Donald M. Gleason, Louis Lacombe, Fred Saad, J. A. Goas, Nicholas J. Vogelzang, Paul F. Schellhammer, Anthony L. Patterson and Michael Sarosdy and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and The Journal of Urology.

In The Last Decade

P. Venner

12 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma

2002 1.2k citations Fred Saad, Donald M. Gleason et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P. Venner Canada	6	1.1k	887	520	237	209	12	1.3k
J.L. Chin Canada	6	751 0.7×	583 0.7×	384 0.7×	210 0.9×	131 0.6×	8	966
Clive Sinoff Canada	7	1.2k 1.1×	353 0.4×	502 1.0×	319 1.3×	282 1.3×	10	1.4k
Narciso Hernández Toriz Mexico	4	596 0.6×	353 0.4×	168 0.3×	100 0.4×	337 1.6×	6	799
Amy Kupic United States	3	603 0.6×	347 0.4×	175 0.3×	101 0.4×	337 1.6×	5	798
Richard Leff United States	9	529 0.5×	190 0.2×	228 0.4×	158 0.7×	72 0.3×	14	659
G. Luschin-Ebengreuth Austria	12	1.1k 1.0×	247 0.3×	359 0.7×	123 0.5×	294 1.4×	27	1.3k
L.V.A.M. Beex Netherlands	14	573 0.5×	177 0.2×	153 0.3×	118 0.5×	67 0.3×	33	844
Gerard Powell Australia	14	527 0.5×	468 0.5×	114 0.2×	187 0.8×	62 0.3×	27	959
A. Galid Austria	9	519 0.5×	167 0.2×	155 0.3×	65 0.3×	113 0.5×	27	748
Pu‐Yun OuYang China	19	528 0.5×	489 0.6×	205 0.4×	410 1.7×	12 0.1×	48	1.1k

Countries citing papers authored by P. Venner

Since Specialization

Citations

This map shows the geographic impact of P. Venner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Venner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Venner more than expected).

Fields of papers citing papers by P. Venner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Venner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Venner. The network helps show where P. Venner may publish in the future.

Co-authorship network of co-authors of P. Venner

This figure shows the co-authorship network connecting the top 25 collaborators of P. Venner. A scholar is included among the top collaborators of P. Venner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Venner. P. Venner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Paulden, Mike, et al.. (2019). Cost-effectiveness analysis of metformin with enzalutamide in the metastatic castrate-resistant prostate cancer setting.. PubMed. 26(6). 10045–10053. 2 indexed citations

Bjarnason, Georg A., Eric Winquist, Christian Kollmannsberger, et al.. (2014). Phase Ii Study of Individualized Sunitinib As First-Line Therapy for Metastatic Clear Cell Renal Cell Cancer (Mrcc). Annals of Oncology. 25. iv292–iv292. 3 indexed citations

Hussain, Maha, Catherine M. Tangen, Celestia S. Higano, et al.. (2012). Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.. Journal of Clinical Oncology. 30(15_suppl). 4–4. 32 indexed citations

Scher, Howard I., Ronald de Wit, William R. Berry, et al.. (2010). Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial.. Journal of Clinical Oncology. 28(15_suppl). 4509–4509. 20 indexed citations

Gleason, Donald M., Robin Murray, N. Simon Tchekmedyian, et al.. (2004). Continuing benefit of zoledronic acid for the prevention of skeletal complications in men with advanced prostate cancer. Journal of Clinical Oncology. 22(14_suppl). 4575–4575. 10 indexed citations

Chin, J.L., Fred Saad, Donald M. Gleason, et al.. (2004). Clinical benefit of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer based on history of skeletal complications. Journal of Clinical Oncology. 22(14_suppl). 4576–4576. 5 indexed citations

Saad, Fred, Donald M. Gleason, Robin Murray, et al.. (2004). Continuing benefit of zoledronic acid for the prevention of skeletal complications in men with advanced prostate cancer. Journal of Clinical Oncology. 22(14_suppl). 4575–4575. 6 indexed citations

Saad, Fred, Donald M. Gleason, Robin Murray, et al.. (2002). A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma. JNCI Journal of the National Cancer Institute. 94(19). 1458–1468. 1242 indexed citations breakdown →

Soloway, Mark S., Paul F. Schellhammer, P. Venner, et al.. (1996). A Controlled Trial of Casodex™(Bicalutamide) vs. Flutamide,Each in Combination with LuteinisingHormone-Releasing HormoneAnalogue Therapy in Patients withAdvanced Prostate Cancer. European Urology. 29(2). 105–109. 20 indexed citations

10.

Venner, P.. (1992). Megestrol Acetate in the Treatment of Metastatic Carcinoma of the Prostate. Oncology. 49(2). 22–27. 1 indexed citations

11.

Fradet, Yves, et al.. (1987). Total androgen blockade for metastatic cancer of prostate. European Journal of Cancer and Clinical Oncology. 23(8). 1233–1233. 4 indexed citations

12.

Fradet, Yves, et al.. (1987). Total Androgen Blockade for Metastatic Cancer of Prostate. The Journal of Urology. 137(6). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact